vTv Therapeutics Inc.
N.C. · Biopharma, Biotechnology, Healthcare
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d
Key facts
- Headquarters
- N.C.
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (VTVT)
- Website
- vtvtherapeutics.com
- Company page
Recent activity at vTv Therapeutics Inc.
- : SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its at-the-market sales program to the maximum amount allowed. This filing includes a legal opinion from Dechert LLP regarding the legality of the shares issued under the program. This expansion allows the company to take full advantage of market conditions for capital raising, which could support its operations and growth strategies moving forward.
- : SEC 8-K (7.01): On March 10, 2026, vTv Therapeutics, Inc. posted an updated slide presentation on its website, which is included as Exhibit 99.1 in the Form 8-K filing. This presentation is intended for use in various meetings with investors, analysts, and other interested parties. It allows the Company to update stakeholders on its developments and may be modified or replaced in future filings. The strategic implication of this update is to strengthen investor engagement and communication regarding the Company's activities and performance.
- : SEC 8-K (7.01): On February 26, 2026, vTv Therapeutics, Inc. issued a Regulation FD disclosure by posting an updated slide presentation on its website. The presentation is intended for use in meetings with investors, analysts, and other stakeholders, highlighting the company's recent developments and future strategy. This presentation can be amended or updated at any time and will be communicated through subsequent filings, ensuring that stakeholders receive timely information. The nature of the information shared is designed to enhance transparency and facilitate discussions regarding the company's performance and strategic initiatives.
- : vTv Therapeutics Enters Second Amendment to License Agreement with Newsoara Biopharma
- : SEC 8-K (1.01): On January 30, 2026, vTv Therapeutics LLC entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. This amendment expands Newsoara's rights to the Company’s PDE4 inhibitor, HPP737, to include all countries worldwide contingent upon an upfront fee payment of $20 million. In addition to the upfront fee, Newsoara is obligated to pay vTv LLC up to $50 million in development milestones and $65 million in sales-related milestones. The original License Agreement was established on May 31, 2018, and a previous amendment to expand the rights lapsed in June 2025, making this Second Amendment a significant legal development.
- : vTv Therapeutics
- : vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
- : vTv Therapeutics Inc.
- : vTv Therapeutics Inc.
- : vTv Therapeutics Inc.
vTv Therapeutics Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2024 | Venture | $51.0M |
| Oct 2019 | Seed | $2.0M |
| Jul 2019 | Seed | $4.0M |
| Jan 2019 | Seed | $1.5M |
| Aug 2018 | Venture | Undisclosed |
Leadership
- Howard Weiner, Director
- Noel Spiegel, Director
- Paul Savas, Director
- John Fry, Director
- Hersh Kozlov, Director
- Jeffrey Kindler, Director
- Howard Weiner, Director
- Noel Spiegel, Director
- Paul Savas, Director
- John Fry, Director
- Hersh Kozlov, Director
- Jeffrey Kindler, Executive Officer, Director
Verified email and direct lines for vTv Therapeutics Inc.’s decision-makers are on Fundz. See plans
vTv Therapeutics Inc. in the news
- vTv Therapeutics Announces Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes - UNC Health (Feb 23, 2021)
- Aditum Bio Announces Formation of Third Company, Anteris Bio - PR Newswire (Dec 15, 2020)
- ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times (Oct 01, 2025)
- Cantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple Sclerosis - PR Newswire (May 13, 2026)
Companies similar to vTv Therapeutics Inc.
- AbbVie Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Praxis Precision Medicines, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Milestone Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About vTv Therapeutics Inc.: questions and answers
What does vTv Therapeutics Inc. do?
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary d
Where is vTv Therapeutics Inc. headquartered?
vTv Therapeutics Inc. is headquartered in N.C..
Has vTv Therapeutics Inc. raised funding?
Yes. Fundz has recorded 5 funding events for vTv Therapeutics Inc.. The most recent, $51.0M, was in Mar 2024.
What is the latest news on vTv Therapeutics Inc.?
On May 13, 2026, SEC 8-K (8.01): On May 13, 2026, vTv Therapeutics Inc. filed a prospectus supplement with the SEC to increase the number of shares of Class A common stock offered under its at-the-market sales program to the maximum amount allowed. This filing includes a legal opinion from Dechert LLP regarding the
Is vTv Therapeutics Inc. a public company?
Yes. vTv Therapeutics Inc. is publicly traded under the ticker VTVT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy